Verrica Pharmaceuticals (STU:1NE) Debt-to-Equity : 30.81 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Verrica Pharmaceuticals Debt-to-Equity?

Verrica Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.93 Mil. Verrica Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €41.80 Mil. Verrica Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €1.39 Mil. Verrica Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 30.81.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Verrica Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

STU:1NE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.72 Max: 30.8
Current: 30.8

During the past 8 years, the highest Debt-to-Equity Ratio of Verrica Pharmaceuticals was 30.80. The lowest was 0.00. And the median was 0.72.

STU:1NE's Debt-to-Equity is ranked worse than
99.91% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs STU:1NE: 30.80

Verrica Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Verrica Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals Debt-to-Equity Chart

Verrica Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.13

1.33

0.04

2.30

Verrica Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.03	1.04	2.30	30.81

Competitive Comparison of Verrica Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Verrica Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verrica Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Verrica Pharmaceuticals's Debt-to-Equity falls into.

Verrica Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Verrica Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.642	+	41.091)	/	18.123
	=	2.30

Verrica Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.929	+	41.799)	/	1.387
	=	30.81

Verrica Pharmaceuticals (STU:1NE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Verrica Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Verrica Pharmaceuticals (STU:1NE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (STU:1NE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

VRCA:USA

Address

44 West Gay Street, Suite 400, West Chester, PA, USA, 19380

Website

https://www.verrica.com

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

Verrica Pharmaceuticals (STU:1NE) Headlines

No Headlines